Topotecan (hycamptin) and topotecan-containing regimens in the treatment of hematologic malignancies.

This publication has 14 references indexed in Scilit:

• Cyclophosphamide, Ara-C and Topotecan (CAT) for Patients With Refractory or Relapsed Acute Leukemia
  Leukemia & Lymphoma, 2000
• Topoisomerase I inhibitors: selectivity and cellular resistance
  Drug Resistance Updates, 1999
• Topotecan and Cytarabine Is an Active Combination Regimen in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
  Journal of Clinical Oncology, 1999
• Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study
  Leukemia, 1999
• Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study
  Investigational New Drugs, 1999
• Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study.
  Journal of Clinical Oncology, 1998
• Results of Topotecan Single-Agent Therapy in Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
  Leukemia & Lymphoma, 1998
• Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial
  British Journal of Haematology, 1997
• Cytotoxic Effects of Topotecan Combined With Various Anticancer Agents in Human Cancer Cell Lines
  JNCI Journal of the National Cancer Institute, 1996
• The concentration-dependent diversity of effects of DNA topoisomerase I and II inhibitors on the cell cycle of HL-60 cells*1
  Experimental Cell Research, 1991